Pd01-08 Quality of Treatment With Targeted Therapies for Advanced Prostate Cancer by Specialist: Do Patients Who Are Managed by Urologists Fare Differently?

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) I (PD01)1 May 2024PD01-08 QUALITY OF TREATMENT WITH TARGETED THERAPIES FOR ADVANCED PROSTATE CANCER BY SPECIALIST: DO PATIENTS WHO ARE MANAGED BY UROLOGISTS FARE DIFFERENTLY? Kassem Faraj, Mary Oerline, Samuel Kaufman, Avinash Maganty, Megan Caram, Vahakn Shahinian, and Brent Hollenbeck Kassem FarajKassem Faraj , Mary OerlineMary Oerline , Samuel KaufmanSamuel Kaufman , Avinash MagantyAvinash Maganty , Megan CaramMegan Caram , Vahakn ShahinianVahakn Shahinian , and Brent HollenbeckBrent Hollenbeck View All Author Informationhttps://doi.org/10.1097/01.JU.0001009540.33579.43.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Urologists are increasingly prescribing oral targeted therapies in men with advanced prostate cancer (Figure 1). Though well-tolerated, these therapies require close monitoring due to the possibility of adverse cardiometabolic events. Further, these medications are expensive, often subjecting patients to high out-of-pocket costs that can lead to coping strategies, such as non-adherence to treatment. METHODS: A 20% sample of National Medicare claims was used to perform a retrospective cohort study of Medicare beneficiaries with advanced prostate cancer treated with a targeted therapy between 2012 and 2019. The primary outcome was a composite measure comprised of a hospital or emergency department visit for a cardiometabolic event within 6 months of starting an oral targeted therapy. Secondary outcomes included monthly out-of-pocket costs and treatment adherence within the first 6 months of therapy. RESULTS: There were 1,212 (23%) and 4,124 (77%) patients who were prescribed a targeted therapy for the first time by a urologist and medical oncologist, respectively. No difference in the composite adverse event measure was observed in those managed by urologists or medical oncologists (Figure 2, 4.2% vs 4.7%, respectively, p=0.49). Monthly out-of-pocket costs, in those without low-income subsidies, did not vary by specialty ($772 vs $790, p=0.58). Adherence to treatment did not vary in men managed by urologists or medical oncologists (75% vs 74%, respectively, p=0.64). CONCLUSIONS: The specialty of the physician prescribing a targeted therapy to men with advanced prostate cancer was not associated with the risk of a cardiometabolic adverse event. Further, management by a urologist was not associated with increased out-of-pocket costs or treatment nonadherence. This study provides further support for urologists' increased role in managing advanced prostate cancer. Download PPTDownload PPT Source of Funding: Dr. Faraj is supported by the NCI (T32 CA180984). This study was supported by funding from the NCI (R01 CA275993, R01 HS025707) © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e66 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Kassem Faraj More articles by this author Mary Oerline More articles by this author Samuel Kaufman More articles by this author Avinash Maganty More articles by this author Megan Caram More articles by this author Vahakn Shahinian More articles by this author Brent Hollenbeck More articles by this author Expand All Advertisement PDF downloadLoading ...